Loading clinical trials...
Loading clinical trials...
Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setti...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Mirati Therapeutics Inc.
NCT06149481 · Metastatic Colorectal Cancer
NCT07446322 · Ras-mutated Metastatic Colorectal Cancer, mCRC, and more
NCT07536113 · Metastatic Colorectal Cancer (CRC)
NCT06820463 · Metastatic Colorectal Cancer
NCT07416552 · Metastatic Colorectal Cancer
Local Institution - 010-855-E
Alabaster, Alabama
Local Institution - 010-855-B
Bessemer, Alabama
Local Institution - 010-855-D
Birmingham, Alabama
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions